Nice to see an XXII poster who has conviction and faith in their investment. Even though imo Henry and crew have been miserable in moving the company in the right direction.
Unlike some who continually bounce from the devil's advocate to sainthood in the blink of an eye regarding HENRY'S shortcomings over the years being engaged with the FDA. The FDA's inability to protect the citizens of the United States is appalling and should be addressed by the present administration imo.
The FDA has historically been lame causing many deaths from inaction by failing to reign in BIG TOBACCO and BIG PHARMA for decades.
The conviction of this member regarding XXII has deep roots. The present position taken has been due to incompetence on numerous levels on a needlessly long road to projected success by XXII corporate.
What a laugher in moving an agenda! Why would XXII partner with another genetic company to assist in the cannibus, hemp, and tobacco strains if in fact XXII has conveyed to their investors for years they are on point with their I/P PORTFOLIO HELD.
Just another reason why one should be very skeptical of XXII and their botanical genetic modification portfolio. One has to wonder WHY if XXII corporate already had the goods to make it happen. Just maybe that is why BAT dropped Henry and our I/P portfolio agreements.
...using XXII IP of course, will help move the agenda